Get access to our best features
Get access to our best features
Published 1 year ago

NCI-led clinical trial results in the first approval of a treatment for advanced alveolar soft part sarcoma

Summary by Ground News
The immunotherapy drug atezolizumab (Tecentriq) was recently approved by the U.S. Food and Drug Administration. About 80 people in the United States are diagnosed with ASPS every year. About a third of patients responded to the treatment with some degree of tumor shrinkage.

0 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • 100% of the sources are Center
100% Center

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics